Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Short-term Investments (2022 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Short-term Investments data on record, last reported at $1.0 million in Q1 2025.

  • For Q1 2025, Short-term Investments changed N/A year-over-year to $1.0 million; the TTM value through Mar 2025 reached $1.0 million, changed N/A, while the annual FY2024 figure was $1.0 million, 98.94% down from the prior year.
  • Short-term Investments reached $1.0 million in Q1 2025 per INDV's latest filing, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $94.0 million in Q4 2023 and bottomed at $1.0 million in Q4 2024.
  • Average Short-term Investments over 3 years is $32.0 million, with a median of $1.0 million recorded in 2024.
  • The widest YoY moves for Short-term Investments: up 98.94% in 2024, down 98.94% in 2024.
  • A 3-year view of Short-term Investments shows it stood at $94.0 million in 2023, then crashed by 98.94% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $1.0 million in Q1 2025, $1.0 million in Q4 2024, and $94.0 million in Q4 2023.